ArticleThe American journal of pathology2011
NF-κB inhibition protects against tumor-induced cardiac atrophy in vivo.
Article in The American journal of pathology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 66 citations in OpenAlex.
- Whole Genome Sequence Analysis of Weight Loss in 16 972 Participants With COPD Reveals Novel Risk Loci in DRAIC and RFX3.Journal of cachexia, sarcopenia and muscle · 2026Article
- Cardiac function of colorectal cancer mice is remotely controlled by gut microbiota: regulating serum metabolites and myocardial cytokines.Animal microbiome · 2025Article
- Cardiac wasting in patients with cancer.Basic research in cardiology · 2025Review
- Evaluation of selected antidiabetics in cardiovascular complications associated with cancer cachexia.Molecular and cellular biochemistry · 2023Article
- Review
- Inhibition of activin A receptor signalling attenuates age-related pathological cardiac remodelling.Disease models & mechanisms · 2022Article
- Review
- Article
- Two Types of Mouse Models for Sarcopenia Research: Senescence Acceleration and Genetic Modification Models.Journal of bone metabolism · 2021Article
- Advanced cancer is also a heart failure syndrome: a hypothesis.Journal of cachexia, sarcopenia and muscle · 2021Review
- Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia and asthenia.Journal of cachexia, sarcopenia and muscle · 2020Review
- IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.Lung cancer (Amsterdam, Netherlands) · 2019Article
- Inter-tissue communication in cancer cachexia.Nature reviews. Endocrinology · 2018Review
- Cardiac muscle wasting in individuals with cancer cachexia.ESC heart failure · 2017Article
- Molecular mechanism of sarcopenia and cachexia: recent research advances.Pflugers Archiv : European journal of physiology · 2017Review
- Prostate cancer reduces endurance exercise capacity in association with reductions in cardiac and skeletal muscle mass in the rat.American journal of cancer research · 2017Article
- Post-translationally modified muscle-specific ubiquitin ligases as circulating biomarkers in experimental cancer cachexia.American journal of cancer research · 2017Article
- The Early Predictive Value of Right Ventricular Strain in Epirubicin-Induced Cardiotoxicity in Patients with Breast Cancer.Acta Cardiologica Sinica · 2016Article
- Pay attention to cardiac remodeling in cancer cachexia.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Review
- Understanding cachexia as a cancer metabolism syndrome.Oncogenesis · 2016Review
Corrections and comments
- Erratum issuedLi, Lugi [corrected to Li, Luge]
Authors and funding
12 authors at 2 institutions in 3 countries.
Funding
Abstract
Cancer cachexia is a severe wasting syndrome characterized by the progressive loss of lean body mass and systemic inflammation. It occurs in approximately 80% of patients with advanced malignancy and is the cause of 20% to 30% of all cancer-related deaths. The mechanism by which striated muscle loss occurs is the tumor release of pro-inflammatory cytokines, such as IL-1, IL-6, and TNF-α. These cytokines interact with their cognate receptors on muscle cells to enhance NF-κB signaling, which then mediates muscle loss and significant cardiac dysfunction. Genetic inhibition of NF-κB signaling has demonstrated its predominant role in skeletal muscle loss. Therefore, we tested two novel drugs designed to specifically inhibit NF-κB by targeting the IκB kinase (IKK) complex: Compound A and NEMO binding domain (NBD) peptide. Using an established mouse model of cancer cachexia (C26 adenocarcinoma), we determined how these drugs affected the development of tumor-induced cardiac atrophy and function. Echocardiographic and histological analysis revealed that both Compound A and NBD inhibit cardiac NF-κB activity and prevent the development of tumor-induced systolic dysfunction and atrophy. This protection was independent of any effects of the tumor itself (Compound A) or tumor-secreted cytokines (NBD). This study identifies for the first time, to our knowledge, that drugs targeting the IKK complex are cardioprotective against cancer cachexia-induced cardiac atrophy and systolic dysfunction, suggesting therapies that may help reduce cardiac-associated morbidities found in patients with advanced malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.